Technical Data Sheet
HGH Fragment 176-191
Also Known As: HGH Frag, AOD Fragment, Frag 176-191, HGH Fragment, Fragment 176-191, HGH 176-191, Growth hormone fragment 176-191, GH fragment 176-191, Lipolytic GH fragment, Fat-loss fragment, Frag176-191, C-terminal HGH fragment 176-191, Anti-obesity GH fragment
Scan To View Profile
| Evidence Tier | Research Compound |
|---|---|
| Category | Muscle Growth & Performance |
| Class | Synthetic fragment of HGH C-terminus (residues 176-191) |
| Molecular Target | Beta-3 adrenergic receptors; stimulates lipolysis without GH receptor binding; no IGF-1 elevation |
| Sequence | 16-aa C-terminal lipolytic fragment of human growth hormone (residues 176-191) |
| Molecular Weight | ~1817 g/mol |
| CAS | 66004-57-7 |
| Parent | Human growth hormone |
| Mechanism | It isolates the specific sequence of amino acids responsible for fat breakdown (lipolysis). It attaches to fat cells and forces them to release stored fat without activating the IGF-1 growth pathways. |
| Studied For | Lipolysis / fat loss, Adipose reduction, Visceral fat reduction, Body composition improvement, Subcutaneous fat burning, Fat oxidation, Anti-obesity research, Weight management, Metabolic rate enhancement, Fat-loss peptide research, Abdominal fat research, Beta-3 adrenergic lipolysis, Lean mass preservation during fat loss, GH-fragment weight research |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | bacteriostatic water; slow, no foaming |
| Storage Temperature | -4°F, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Disulfide loop is oxidation-sensitive. |
| Regulatory | Not FDA-approved; research chemical. Named on the WADA 2026 Prohibited List under S2.2.3 (growth hormone fragments); prohibited at all times and a non-Specified substance. |
| Sources |